[
  {
    "ts": null,
    "headline": "Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients",
    "summary": "On Tuesday, Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib for locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2 negative breast cancer. These data will be presented at the 2024 San Antonio Breast Cancer Symposium. Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safe",
    "url": "https://finnhub.io/api/news?id=d38dcd2737fba37c9b3285ad1e0fb7ef4551c2c10430cb8845ae453c33d3aa3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733854987,
      "headline": "Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients",
      "id": 131905557,
      "image": "https://media.zenfs.com/en/Benzinga/7f52ad0ab6f02f41c64fd7b2b1af5a02",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Tuesday, Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib for locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2 negative breast cancer. These data will be presented at the 2024 San Antonio Breast Cancer Symposium. Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safe",
      "url": "https://finnhub.io/api/news?id=d38dcd2737fba37c9b3285ad1e0fb7ef4551c2c10430cb8845ae453c33d3aa3f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=fdc20f895838159e1b0561a0125219a7a0af72ca6cd41e0f3aca42fd1222f5c7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848740,
      "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131935413,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=fdc20f895838159e1b0561a0125219a7a0af72ca6cd41e0f3aca42fd1222f5c7"
    }
  },
  {
    "ts": null,
    "headline": "Editas Stock Rises on Updated Data From SCD Study of Reni-Cel",
    "summary": "EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.",
    "url": "https://finnhub.io/api/news?id=fb502d9483d4ea5940a7b72cc0a330cce5c854d79a81764e3d87c4c2a42fa63b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733847180,
      "headline": "Editas Stock Rises on Updated Data From SCD Study of Reni-Cel",
      "id": 131905082,
      "image": "https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.",
      "url": "https://finnhub.io/api/news?id=fb502d9483d4ea5940a7b72cc0a330cce5c854d79a81764e3d87c4c2a42fa63b"
    }
  },
  {
    "ts": null,
    "headline": "KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential",
    "summary": "Kodiak stock surges as Jefferies upgrades it to a \"BUY\" rating based on the significant potential of its pipeline candidates for retinal disease indications.",
    "url": "https://finnhub.io/api/news?id=c5cd67935120a1b861a6ab66837ee612e8a347f7c715b3593cf1b8251cd55757",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733845380,
      "headline": "KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential",
      "id": 131905559,
      "image": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Kodiak stock surges as Jefferies upgrades it to a \"BUY\" rating based on the significant potential of its pipeline candidates for retinal disease indications.",
      "url": "https://finnhub.io/api/news?id=c5cd67935120a1b861a6ab66837ee612e8a347f7c715b3593cf1b8251cd55757"
    }
  },
  {
    "ts": null,
    "headline": "RSV prophylactic market to reach $6.2bn in 8MM by 2030",
    "summary": "As of 2020, the only product marketed for RSV prophylaxis was AstraZeneca/AbbVie's Synagis.",
    "url": "https://finnhub.io/api/news?id=9bfccb10b5fc1f8457586c45295df48b229720a37bd7d9f1604e7307d6d52903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733844834,
      "headline": "RSV prophylactic market to reach $6.2bn in 8MM by 2030",
      "id": 131903970,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2324162019.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "As of 2020, the only product marketed for RSV prophylaxis was AstraZeneca/AbbVie's Synagis.",
      "url": "https://finnhub.io/api/news?id=9bfccb10b5fc1f8457586c45295df48b229720a37bd7d9f1604e7307d6d52903"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance",
    "summary": "NEW YORK, December 10, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer’s full-year 2025 financial guidance.",
    "url": "https://finnhub.io/api/news?id=fbeaa697a35ce4c12f0beca82243b5799fd53582148a996e06d0be5ac1e9c709",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733842800,
      "headline": "Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance",
      "id": 131905564,
      "image": "https://media.zenfs.com/en/business-wire.com/b293656f9de3ceac5854943cb2495e53",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 10, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer’s full-year 2025 financial guidance.",
      "url": "https://finnhub.io/api/news?id=fbeaa697a35ce4c12f0beca82243b5799fd53582148a996e06d0be5ac1e9c709"
    }
  },
  {
    "ts": null,
    "headline": "AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC",
    "summary": "The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.",
    "url": "https://finnhub.io/api/news?id=6c8124ce8920e9326abd00b265431332fde4b7c70d88b7462d3d053056065f31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733841840,
      "headline": "AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC",
      "id": 131903180,
      "image": "https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated advanced EGFR-mutated NSCLC.",
      "url": "https://finnhub.io/api/news?id=6c8124ce8920e9326abd00b265431332fde4b7c70d88b7462d3d053056065f31"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium",
    "summary": "– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safety and tolerability of the combination is generally consistent with the profile of abemaciclib and what has been observed in other clinical trials of vepdegestrant; no significant drug-drug interaction was observed between vepdegestrant and abemaciclib – – Recommended Phase 2 dose ide",
    "url": "https://finnhub.io/api/news?id=fa9e9ed7dbaa7bcfa31149b3a63b3948bc54bf11aa0238f8eb2f794be365b469",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733839500,
      "headline": "Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium",
      "id": 131905057,
      "image": "https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safety and tolerability of the combination is generally consistent with the profile of abemaciclib and what has been observed in other clinical trials of vepdegestrant; no significant drug-drug interaction was observed between vepdegestrant and abemaciclib – – Recommended Phase 2 dose ide",
      "url": "https://finnhub.io/api/news?id=fa9e9ed7dbaa7bcfa31149b3a63b3948bc54bf11aa0238f8eb2f794be365b469"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%",
    "summary": "LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.",
    "url": "https://finnhub.io/api/news?id=9851d384d83cf11ef89e49991d6ffd6add9a8fe4b108bca93b7e33659fd9fd40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733834160,
      "headline": "Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%",
      "id": 131905570,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.",
      "url": "https://finnhub.io/api/news?id=9851d384d83cf11ef89e49991d6ffd6add9a8fe4b108bca93b7e33659fd9fd40"
    }
  },
  {
    "ts": null,
    "headline": "3 Magnificent S&P 500 Dividend Stock Down 35% to Buy and Hold Forever",
    "summary": "The S&P 500 is at an all-time high.  Here are three magnificent S&P 500 dividend stocks down 35% or more to buy and hold forever.  Shares of oil and gas producer Occidental Petroleum (NYSE: OXY) are roughly 47% below the high set in late 2022.",
    "url": "https://finnhub.io/api/news?id=f8de3d0eeaad19dd5649f38de683e84b3f6bfa4d7a9d89ea93fc3156d40b3c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733827680,
      "headline": "3 Magnificent S&P 500 Dividend Stock Down 35% to Buy and Hold Forever",
      "id": 131902753,
      "image": "https://g.foolcdn.com/editorial/images/800369/stock-chart-trending-down-with-man.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The S&P 500 is at an all-time high.  Here are three magnificent S&P 500 dividend stocks down 35% or more to buy and hold forever.  Shares of oil and gas producer Occidental Petroleum (NYSE: OXY) are roughly 47% below the high set in late 2022.",
      "url": "https://finnhub.io/api/news?id=f8de3d0eeaad19dd5649f38de683e84b3f6bfa4d7a9d89ea93fc3156d40b3c52"
    }
  }
]